Study guide

22.6 Transfusion Products & Acute Transfusion Reactions

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

22.6 Transfusion Products & Acute Transfusion Reactions

Key Takeaways Explain This Topic AI

Acute haemolytic transfusion reaction from ABO incompatibility presents within minutes with fever, loin pain, hypotension and haemoglobinuria, and the transfusion must be stopped immediately.

TRALI occurs within 6 hours with hypoxaemia and bilateral infiltrates but a normal or low filling pressure, whereas TACO shows hypertension, raised JVP and responds to diuresis.

Irradiated components are required for Hodgkin lymphoma, purine analogue therapy and intrauterine or neonatal exchange transfusion, to prevent transfusion-associated graft-versus-host disease.

Last updated: September 2026

  • 5. Transfusion Medicine: Products, Triggers & Adverse Reactions
  • Blood Products & Evidence-Based Transfusion Triggers

Packed Red Blood Cells (PRBC): One standard unit raises adult haemoglobin by approximately 10 g/L .

Restrictive Trigger (NICE NG24): Hb <70 g/L with a target post-transfusion level of 70–90 g/L in hemodynamically stable, non-bleeding adult patients.

Acute Coronary Syndrome Trigger: Hb <80 g/L with a target post-transfusion level of 80–100 g/L in patients with active myocardial ischaemia or acute coronary syndrome.

Platelets: One adult therapeutic dose (ATD, pool of 4–6 donor units or single apheresis unit) raises platelet count by 20–40 x 10^9/L .

  • Prophylactic trigger in stable bone marrow failure: <10 x 10^9/L ;
  • Lumbar puncture, central venous catheter placement, or minor surgery: <50 x 10^9/L ;
  • Major surgery, trauma, or active severe bleeding: <50 x 10^9/L ;

Neurosurgery or intraocular ophthalmic surgery: <100 x 10^9/L .

Fresh Frozen Plasma (FFP): Contains all clotting factors and physiological anticoagulants. Indicated for multiple factor deficiencies (severe liver disease, massive transfusion, DIC) with active bleeding or prior to invasive surgery. Standard dose: 12–15 mL/kg . NOT indicated for simple volume expansion or minor non-bleeding coagulopathy.

Cryoprecipitate: Rich in fibrinogen , Factor VIII, vWF, and Factor XIII. Indicated when fibrinogen is <1.5 g/L in bleeding patients (massive obstetric haemorrhage, trauma, DIC). Standard adult dose: 2 pools (equivalent to 10 donor units).

Prothrombin Complex Concentrate (PCC, 4-factor): Contains factors II, VII, IX, X, and proteins C and S. Preferred first-line agent for emergency reversal of warfarin in major, life-threatening haemorrhage (co-prescribed with intravenous vitamin K 5–10 mg); vastly superior to FFP due to rapid normalization of INR (<10 minutes) and minimal volume administration.

  • Acute Transfusion Reactions Acute Dyspnoea During Transfusion
  • |
  • +-----------------------------+-----------------------------+
  • | |
  • TRALI (Non-Cardiogenic) TACO (Cardiogenic Overload)
  • Donor anti-HLA/HNA antibodies - Excessive volume / rapid infusion rate
  • Capillary leak & neutrophil damage - Left ventricular hydrostatic overload
  • Normal JVP, Normal BNP - Elevated JVP, Elevated BNP (>1.5x)
  • Hypotension / fever - Severe Hypertension
  • Bilateral fluffy infiltrates - Bilateral infiltrates + cardiomegaly
  • Treatment: Oxygen, respiratory support - Treatment: Stop, sit up, IV Furosemide

Acute Haemolytic Transfusion Reaction (AHTR):

Cause: ABO incompatibility secondary to clerical identification error. Pre-formed host IgM isohemagglutinins rapidly bind and lyse transfused donor erythrocytes via classical complement activation.

Features: Immediate onset (within minutes) of fever, chills, flushing, retrosternal chest pain, severe flank/loin pain , profound hypotension/shock, dark red urine (haemoglobinuria), and acute DIC.

Management: STOP TRANSFUSION IMMEDIATELY , maintain IV access with vigorous 0.9% saline fluid resuscitation to maintain renal perfusion, check bedside patient ID, and return blood pack and giving set to the transfusion laboratory alongside fresh blood and urine samples.

Transfusion-Related Acute Lung Injury (TRALI):

Pathophysiology: Two-hit mechanism. First hit: Patient's underlying critical illness (sepsis, surgery) primes pulmonary endothelial cells and sequestered neutrophils. Second hit: Infusion of donor plasma containing anti-HLA class I/II or anti-human neutrophil antigen (anti-HNA) antibodies (classically from multiparous female blood donors). These antibodies bind to and activate recipient primed neutrophils within pulmonary capillaries, releasing elastase and reactive oxygen species that damage alveolar-capillary membranes, causing massive non-cardiogenic pulmonary oedema .

Features: Acute dyspnoea, hypoxaemia, fever, hypotension , and bilateral fluffy pulmonary infiltrates developing within 6 hours of transfusion.

Hemodynamics: Normal JVP , normal pulmonary capillary wedge pressure, and normal serum BNP .

Management: Stop transfusion, supportive respiratory therapy (supplemental oxygen, CPAP/BiPAP, mechanical ventilation); avoid aggressive diuresis (patients are frequently hypotensive and intravascularly depleted).

Transfusion-Associated Circulatory Overload (TACO):

Pathophysiology: Pure cardiogenic hydrostatic pulmonary oedema resulting from rapid transfusion of blood volumes that exceed the patient's myocardial or renal circulatory capacity. Risk factors: Age >70, heart failure, renal impairment, severe chronic anaemia.

Features: Acute dyspnoea, orthopnoea, cyanosis, tachycardia, severe hypertension , elevated JVP , bilateral basal crackles, and peripheral oedema developing during or within 6 hours of transfusion.

Diagnostic Markers: Marked post-transfusion elevation of serum BNP / NT-proBNP (>1.5x baseline) and cardiomegaly on CXR.

Management: Stop transfusion immediately , sit the patient upright, administer high-flow oxygen, and give intravenous furosemide (40–80 mg IV) . Prevented by transfusing single units slowly (over 3–4 hours) and pre-transfusion oral furosemide in high-risk patients.

Febrile Non-Haemolytic Transfusion Reaction (FNHTR):

Most common reaction; caused by recipient antibodies reacting against donor leukocytes or accumulated pyrogenic cytokines (IL-1, IL-6, TNF-a) released during storage.

Features: Isolated, benign temperature rise (>=1°C or >38°C) with rigors and chills, without hypotension, respiratory distress, or pain .

Management: Pause transfusion, administer oral paracetamol , exclude ABO mismatch and bacterial sepsis. Transfusion can be restarted at a slower rate once symptoms settle. Universal pre-storage leukodepletion has dramatically reduced incidence.

6. Comparative Table: Differential Diagnosis of Acute Transfusion Reactions

Transfusion Reaction Onset Timing Pathophysiological Mechanism Clinical Examination & Vital Signs Chest Radiograph & Biomarkers Specific Immediate Management

Transfusion-Related Acute Lung Injury (TRALI) Within 6 hours of transfusion Donor anti-HLA / anti-HNA antibodies activate recipient pulmonary neutrophils Acute dyspnoea, hypoxaemia, fever, hypotension ; normal JVP Bilateral diffuse fluffy alveolar infiltrates; normal BNP Stop transfusion; 100% O2; ventilatory support; avoid diuresis

Transfusion-Associated Circulatory Overload (TACO) During or within 6 hours Volume overload exceeding left ventricular reserve (hydrostatic oedema) Acute dyspnoea, orthopnoea, severe hypertension , elevated JVP , crackles Bilateral perihilar congestion, cardiomegaly; elevated BNP (>1.5x) Stop transfusion; sit upright; IV Furosemide 40 mg ; high-flow O2

Acute Haemolytic Reaction (AHTR) Within minutes of starting unit ABO incompatibility (IgM classical complement-mediated intravascular lysis) Fever, chills, severe flank/loin pain , hypotension / shock , DIC Clear lungs initially; positive free haemoglobin in urine; positive DAT Stop transfusion immediately ; aggressive IV normal saline hydration

Febrile Non-Haemolytic (FNHTR) During or within 1–2 hours Host antibodies against donor WBCs; accumulated pyrogenic cytokines Isolated fever rise (>=1°C), rigors, chills; normal BP , no dyspnoea Normal chest radiograph; normal cardiopulmonary markers Pause transfusion; oral paracetamol; resume at slower rate if stable